Evidence map›Paper›PMID 31883128›Full record

ArticleJournal of inherited metabolic disease2020

Choosing between medical management and liver transplant in urea cycle disorders: A conceptual framework for parental treatment decision-making in rare disease.

Maya T Gerstein, Anne R Markus, Kan Z Gianattasio, Cynthia Le Mons, Janice Bartos, David M Stevens, Nicholas Ah Mew

Open access · hybridAbstract read
In one paragraph

Article in Journal of inherited metabolic disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Maya T GersteinDepartment of Health Policy and Management, Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia.ORCID 0000-0003-2035-0828
Anne R MarkusDepartment of Health Policy and Management, Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia.
Kan Z GianattasioDepartment of Health Policy and Management, Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia.
Cynthia Le MonsNational Urea Cycle Disorders Foundation, Pasadena, California.
Janice BartosNational Urea Cycle Disorders Foundation, Pasadena, California.
David M StevensDepartment of Health Policy and Management, Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia.
Nicholas Ah MewRare Disease Institute, Children's National Health System, Washington, District of Columbia.
Milken Institute · USNational Urea Cycle Disorders Foundation · USChildren's National · US

Funding

Training (Career Development) ComponentU54HD061221 · NICHD · CHILDREN'S RESEARCH INSTITUTE · PI GROPMAN, ANDREA LYNNE · 2009 to 2023
$20.8M
6 · The paper itself

Abstract

Urea cycle disorders (UCD) are rare inherited metabolic disorders caused by deficiencies of enzymes and transporters required to convert neurotoxic ammonia into urea. These deficiencies cause elevated blood ammonia, which if untreated may result in death, but even with optimal medical management, often results in recurrent brain damage. There are two major treatments for UCD: medical management or liver transplantation. Both are associated with mortality and morbidity but the evidence comparing outcomes is sparse. Thus, families face a dilemma: should their child be managed medically, or should they undergo a liver transplant? To (a) describe the factors that contribute to treatment choice among parents of children diagnosed with UCD and to (b) organise these factors into a conceptual framework that reflects how these issues interrelate to shape the decision-making experience of this population. Utilising grounded theory, qualitative data were collected through semi-structured interviews with parents (N = 35) and providers (N = 26) of children diagnosed with UCD and parent focus groups (N = 19). Thematic content analysis and selective and axial coding were applied. The framework highlights the life-cycle catalysts that frame families' personal perceptions of risks and benefits and describes the clinical, personal, social, and system factors that drive treatment choice including disease severity, stability, and burden, independence, peer experiences, and cost, coverage and access to quality care. Findings equip providers with evidence upon which to prepare for productive patient interactions about treatment options. They also provide a foundation for the development of patient-centred outcome measures to better evaluate effectiveness of treatments in this population.

Indexed as

Choice BehaviorDecision MakingAdolescentChildChild, PreschoolCost of IllnessDisease ManagementFemaleFocus GroupsHumansInfantInfant, NewbornInterviews as TopicLiver TransplantationMaleParentsdecision-makingliver transplantqualitative researchtreatment choiceurea cycle disorders

Identifiers

PMID31883128
PMCPMC7318329
OpenAlexW2997811258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.